Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and curr...
In the latest edition of STAT's Health Tech newsletter: Nuance's mysterious pric...
A study of thousands of people who were prescribed GLP-based drugs like Ozempic ...
Despite pressure from Congress and advocates, CMS isn’t changing its coverage pl...
As the biotech bash BIO 2023 opens tomorrow, industry leaders are bracing for to...
“I believe we are curing the cancer by using these best drugs early,” said the l...
#ASCO23 A brain cancer that usually strikes in early middle age was slowed down ...
#ASCO23 In a study, ovarian cancer patients treated with Elahere lived for a med...
#ASCO23 A “twinning program” between a San Diego and Tijuana hospital reduced su...
Algorithms that adjust for race raise the threshold for diagnosing a problem in ...
Coherus Biosciences’ biosimilar Yusimry will have a significantly lower cost tha...
CMS announced that it will cover Eisai's Leqembi, upon a traditional approval, i...
Kisqali administered alongside hormone therapy reduced recurrence by 25% in pati...
The new deal also ensures the EU will have access to the latest versions of futu...
Masitinib has received orphan drug designation from the US Food and Drug Adminis...
The approval comes after Briumvi was approved by the US FDA in December last yea...
